Future Perspectives for Antiangiogenic Therapy in Retinal Diseases
The World Health Organization considers eye disorders as the serious problem of our time [1]. According to world statistics, the number of people with visual impairment is 1.3 billion, most of this number are people over 50 years old [2]. Over the past 20 years, developments in the treatment of AMD...
Saved in:
| Main Authors: | M. V. Budzinskaya, A. A. Plyukhova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ophthalmology Publishing Group
2021-10-01
|
| Series: | Oftalʹmologiâ |
| Subjects: | |
| Online Access: | https://www.ophthalmojournal.com/opht/article/view/1634 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New Drugs for the Treatment of DME and the Role of Biomarkers in Predicting Their Effectiveness
by: M. V. Budzinskaya, et al.
Published: (2023-01-01) -
Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter Study
by: Masayuki Ohnaka, et al.
Published: (2025-05-01) -
Experience with Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration
by: M. V. Budzinskaya, et al.
Published: (2023-01-01) -
Comparative efficacy of photodynamic therapy (PDT), ranibizumab, aflibercept monotherapy, and combination therapies for polypoidal choroidal vasculopathy: a network meta-analysis of randomized controlled trials
by: Miguel A. Quiroz-Reyes, et al.
Published: (2025-07-01) -
Functional and Anatomical Outcomes of Faricimab in Previously Treated Wet Age-Related Macular Degeneration: Systematic Review and Pooled Analysis
by: Ali Khodor, et al.
Published: (2025-07-01)